Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Phase I/II Study of ATN-161 and Carboplatin in Adult Patients With Recurrent Intracranial Malignant Glioma
RATIONALE: ATN-161 may stop the growth of tumor cells by blocking blood flow to the tumor.
Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. Giving
ATN-161 together with carboplatin may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of ATN-161 when
given together with carboplatin and to see how well they work in treating patients with
recurrent malignant glioma.
Status | Completed |
Enrollment | 82 |
Est. completion date | January 2008 |
Est. primary completion date | January 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed intracranial malignant glioma - Original low-grade glioma histology allowed provided there is subsequent histologic confirmation of malignant glioma - Any of the following diagnoses: - Glioblastoma multiforme - Gliosarcoma - Anaplastic astrocytoma - Anaplastic oligodendroglioma - Anaplastic mixed oligoastrocytoma - Malignant astrocytoma not otherwise specified - Recurrent disease - Must have failed prior radiotherapy - Must have confirmation of true progressive disease (rather than radiation necrosis) based upon either positron emission tomography or thallium scanning, MR spectroscopy, or surgical documentation of disease if radiographic recurrence is within the high-dose radiation field (for patients who underwent prior interstitial brachytherapy or stereotactic radiosurgery) - Prior recent resection of recurrent or progressive tumors allowed if all of the following criteria are met: - Recovered from prior surgery - Evaluable disease after resection - Unequivocal evidence of tumor progression by MRI - Steroid dose must be stable for = 5 days prior to MRI PATIENT CHARACTERISTICS: - Karnofsky performance status 60-100% - Life expectancy > 8 weeks - WBC = 3,000/mm³ - Absolute neutrophil count = 1,500/mm³ - Platelet count = 100,000/mm³ - Hemoglobin = 10 g/dL (transfusion allowed) - AST < 2.5 times upper limit of normal (ULN) - Bilirubin < 2.5 times ULN - Creatinine < 1.5 mg/dL OR creatinine clearance = 60 mL/min - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 1 month after completion of study treatment - No significant medical illness that would preclude study treatment - No history of other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix) unless disease is in complete remission and off all therapy for = 1 year - No active infection or serious intercurrent medical illness - No disease that will obscure toxicity or dangerously alter drug metabolism - Able to undergo MRI scan and receive contrast agents for perfusion scanning PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Recovered from prior therapy - At least 28 days since prior cytotoxic therapy - At least 14 days since prior vincristine - At least 42 days since prior nitrosoureas - At least 21 days since prior procarbazine - At least 7 days since prior interferon, tamoxifen, thalidomide, isotretinoin, or other noncytotoxic agents (radiosensitizer does not count) - At least 14 days since prior noncytotoxic investigational agents - At least 42 days since prior radiotherapy - No prior cisplatin, carboplatin, oxaliplatin, or platinum-containing analogue - No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF) - No other concurrent anticancer therapy (including chemotherapy, radiotherapy, hormonal therapy, or immunotherapy) - No other concurrent investigational drugs |
Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institutes of Health Clinical Center (CC) | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety | Yes | ||
Primary | Maximum tolerated dose (phase I) | Yes | ||
Primary | Progression-free survival at 6 months | No | ||
Primary | Response rate (phase I) | No | ||
Primary | Overall survival | No | ||
Secondary | Efficacy | No | ||
Secondary | Response rate (phase II) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 |